NYSEAMERICAN:IGC

IGC Pharma (IGC) Stock Forecast, Price & News

$0.30

-0.01 (-3.22%)

(As of 06/9/2023 ET)

Compare

Today's Range: $0.30
▼
$0.32
50-Day Range: N/A
52-Week Range: $0.28
▼
$0.74

Volume: 124,205 shs
Average Volume: 136,655 shs
Market Capitalization: $15.98 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About IGC Pharma (NYSEAMERICAN:IGC) Stock

IGC Pharma, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The firm is involved in researching the application of cannabinoids, such as Tetrahydrocannabinol and Cannabidiol in combination with other compounds to address various ailments, including Alzheimer's disease. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment is involved in the rental of heavy construction equipment, execution of construction contracts, and purchase and resale of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Receive IGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter.

IGC Stock News Headlines

June 6, 2023 | finance.yahoo.com

IGC Pharma Receives Notice of Allowance for Patent on Seizures

June 5, 2023 | finance.yahoo.com

IGC Pharma’s Advisor and Inventor of Drug Candidate TGR-63 Receives Award

June 10, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 18, 2023 | finance.yahoo.com

IGC Pharma to Present at LD Micro Invitational XIII

May 8, 2023 | marketwatch.com

8-K: IGC Pharma, Inc.

April 30, 2023 | americanbankingnews.com

IGC Pharma (NYSEAMERICAN:IGC) Stock Passes Above Two Hundred Day Moving Average of $0.00

April 19, 2023 | marketwatch.com

BioMedNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Announces Participation in Upcoming Planet MicroCap Showcase

April 18, 2023 | finance.yahoo.com

IGC Pharma, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & Hold 1x1 Meetings on Thursday, April 27, 2023

June 10, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

March 22, 2023 | marketwatch.com

BioMedNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) to Attend Investor Summit

March 22, 2023 | finance.yahoo.com

IGC Pharma to Attend Investor Summit

March 20, 2023 | finance.yahoo.com

IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.

March 5, 2023 | benzinga.com

India Globalization Capital Inc. (NYSE American: IGC) Leads the Way Forward with Revolutionary Cannabis-Based Treatment for Alzheimer's Symptoms

February 15, 2023 | msn.com

India Globalization Capital GAAP EPS of -$0.04, revenue of $0.33M

February 15, 2023 | benzinga.com

IGC Q3 2023 Revenue Grows 133% YoY, What About Net Loss?

February 14, 2023 | finance.yahoo.com

IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022

February 8, 2023 | finance.yahoo.com

IGC to be Featured in Feb. 10 Radius Research Investor Webinar

January 27, 2023 | reuters.com

IGC.P - | Stock Price & Latest News | Reuters

January 5, 2023 | benzinga.com

India Globalization Cap Stock (AMEX:IGC), Quotes and News Summary

January 4, 2023 | finance.yahoo.com

IGC Receives No Objection Letter from Health Canada

December 20, 2022 | finance.yahoo.com

IGC Announces Updated Life Sciences Presentation

December 7, 2022 | finance.yahoo.com

IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act

December 1, 2022 | finance.yahoo.com

IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease

November 30, 2022 | finance.yahoo.com

IGC to Present at the RHK 2022 Disruptive Growth Conference

November 1, 2022 | finance.yahoo.com

IGC Reports Financial Results for Second Fiscal Quarter Ended Sept. 30, 2022

September 21, 2022 | seekingalpha.com

India Globalization stock rises on US patent linked to treating Alzheimer's using THC

September 21, 2022 | finance.yahoo.com

IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC

See More Headlines

IGC Price History

30 days | 90 days | 365 days | Advanced Chart

IGC Company Calendar

Last Earnings: 2/10/2020
Today: 6/10/2023
Next Earnings (Estimated): 6/21/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Electronic parts & equipment, not elsewhere classified
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:IGC
CUSIP: N/A
CIK: 1326205
Web: www.igcinc.us
Phone: (301) 983-0998
Fax: 240-465-0273
Employees: 50
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-15,020,000.00
Net Margins: -1,610.48%
Pretax Margin: -1,610.48%
Return on Equity: -66.26%
Return on Assets: -60.11%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 6.90
Quick Ratio: 4.13

Sales & Book Value

Annual Sales: $400,000.00
Price / Sales: 39.94
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.47 per share
Price / Book: 0.64

Miscellaneous

Outstanding Shares: 53,080,000
Free Float: 44,850,000
Market Cap: $15.98 million
Optionable: Optionable
Beta: 2.32

Key Executives

Ram Mukunda
President, Chief Executive Officer & Director

Claudia Grimaldi
CFO, Director, Chief Compliance Officer & VP

Jagadeesh Rao
Chief Scientific Officer

Rohit Goel
Chief Accounting Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IGC Stock - Frequently Asked Questions

How have IGC shares performed in 2023?: IGC Pharma's stock was trading at $0.40 at the beginning of the year. Since then, IGC shares have decreased by 24.8% and is now trading at $0.3010.
View the best growth stocks for 2023 here.
Are investors shorting IGC Pharma?: IGC Pharma saw a decrease in short interest in May. As of May 15th, there was short interest totaling 896,700 shares, a decrease of 14.6% from the April 30th total of 1,050,000 shares. Based on an average daily volume of 102,400 shares, the days-to-cover ratio is currently 8.8 days.
View IGC Pharma's Short Interest.
When is IGC Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 21st 2023.
View our IGC earnings forecast.
How were IGC Pharma's earnings last quarter?: IGC Pharma, Inc. (NYSEAMERICAN:IGC) announced its quarterly earnings data on Monday, February, 10th. The construction company reported ($0.04) earnings per share (EPS) for the quarter. The construction company earned $0.57 million during the quarter. IGC Pharma had a negative trailing twelve-month return on equity of 66.26% and a negative net margin of 1,610.48%.
What other stocks do shareholders of IGC Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IGC Pharma investors own include GW Pharmaceuticals (GWPH), Alibaba Group (BABA), Tilray (TLRY), Cronos Group (CRON), Micron Technology (MU), NewAge (NBEV), Advanced Micro Devices (AMD), Ford Motor (F) and NIO (NIO).

What is IGC Pharma's stock symbol?: IGC Pharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IGC."
Who are IGC Pharma's major shareholders?: IGC Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.21%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Ram Mukunda and Richard K Prins.
View institutional ownership trends.
How do I buy shares of IGC Pharma?: Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IGC Pharma's stock price today?: One share of IGC stock can currently be purchased for approximately $0.30.
How much money does IGC Pharma make?: IGC Pharma (NYSEAMERICAN:IGC) has a market capitalization of $15.98 million and generates $400,000.00 in revenue each year. The construction company earns $-15,020,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.
How can I contact IGC Pharma?: IGC Pharma's mailing address is 4336 Montgomery Ave, BETHESDA, MD 20814-4443, United States. The official website for the company is www.igcinc.us. The construction company can be reached via phone at (301) 983-0998, via email at info@igcinc.us, or via fax at 240-465-0273.

This page (NYSEAMERICAN:IGC) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial